NEWS & EVENTS
SomaServe – successful closing of £2m series A funding round
SomaServe Ltd, a pioneer in nanomedicines for crossing biological barriers today announced that it has completed a highly successful, oversubscribed Series A funding of £2.1m. SomaServe has also secured further IP and global commercial rights to PolyNaut® platform technology (the…
Abcam and SomaServe partnership
Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cells. • Commercialise novel cell delivery platform technology • Develop novel delivery methods for research applications • Revolutionise utility of live cell…
PRODUCTS
OUR VISION
“To pioneer new therapies for crossing the blood brain barrier (BBB) and other biological barriers in collaboration with partners exploiting our proprietary technology, PolyNaut®.”
